DexCom Net Invested Capital from 2010 to 2024
| DXCM Stock | USD 126.65 0.77 0.61% |
Net Invested Capital | First Reported 2010-12-31 | Previous Quarter 4.5 B | Current Value 3.2 B | Quarterly Volatility 1.5 B |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many exotic indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Net Invested Capital |
Latest DexCom's Net Invested Capital Growth Pattern
Below is the plot of the Net Invested Capital of DexCom Inc over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. DexCom's Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Net Invested Capital | 10 Years Trend |
|
Net Invested Capital |
| Timeline |
DexCom Net Invested Capital Regression Statistics
| Arithmetic Mean | 1,923,525,429 | |
| Geometric Mean | 1,448,021,434 | |
| Coefficient Of Variation | 77.08 | |
| Mean Deviation | 1,288,283,848 | |
| Median | 747,000,000 | |
| Standard Deviation | 1,482,632,427 | |
| Sample Variance | 2198198.9T | |
| Range | 3.8B | |
| R-Value | 0.87 | |
| Mean Square Error | 568169.7T | |
| R-Squared | 0.76 | |
| Significance | 0.000023 | |
| Slope | 289,016,679 | |
| Total Sum of Squares | 30774784.8T |
DexCom Net Invested Capital History
About DexCom Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include DexCom income statement, its balance sheet, and the statement of cash flows. DexCom investors use historical funamental indicators, such as DexCom's Net Invested Capital, to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DexCom Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DexCom. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Invested Capital | 4.5 B | 3.2 B |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving together with DexCom Stock
| 0.63 | CI | Cigna Corp Financial Report 3rd of May 2024 | PairCorr |
Moving against DexCom Stock
| 0.83 | ALHC | Alignment Healthcare LLC | PairCorr |
| 0.72 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
| 0.7 | CLOV | Clover Health Investments Earnings Call This Week | PairCorr |
| 0.66 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
| 0.65 | HUM | Humana Inc Financial Report 7th of August 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of DexCom Correlation against competitors. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.987 | Earnings Share 1.53 | Revenue Per Share 9.827 | Quarterly Revenue Growth 0.242 | Return On Assets 0.0679 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.